StockNews.com Initiates Coverage on Trinity Biotech (NASDAQ:TRIB)

Stock analysts at StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a research note issued on Friday. The firm set a “sell” rating on the stock.

Trinity Biotech Stock Up 0.9 %

Shares of NASDAQ:TRIB opened at $0.69 on Friday. Trinity Biotech has a twelve month low of $0.63 and a twelve month high of $3.55. The stock’s 50 day moving average is $0.81 and its 200-day moving average is $1.18. The firm has a market capitalization of $12.37 million, a price-to-earnings ratio of -0.30 and a beta of 1.20.

Institutional Trading of Trinity Biotech

An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC increased its stake in shares of Trinity Biotech plc (NASDAQ:TRIB) by 5.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 378,590 shares of the company’s stock after acquiring an additional 18,780 shares during the quarter. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 78.97% of the stock is owned by institutional investors and hedge funds.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.